Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

72.50CHF
23 May 2018
Change (% chg)

CHF-0.85 (-1.16%)
Prev Close
CHF73.35
Open
CHF73.20
Day's High
CHF73.20
Day's Low
CHF72.05
Volume
51,378
Avg. Vol
65,812
52-wk High
CHF87.10
52-wk Low
CHF63.75

Select another date:

Fri, Apr 27 2018

BRIEF-Basilea Pharmaceutica Appoints Gerrit Hauck As CTO

* GERRIT HAUCK APPOINTED AS CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea: Start Of Clinical Phase 3 Study In Japan

* BASILEA REPORTS START OF CLINICAL PHASE 3 STUDY IN JAPAN BY ASAHI KASEI PHARMA WITH ANTIFUNGAL ISAVUCONAZOLE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

BRIEF-Basilea Pharmaceutica Licenses Late-Stage Oncology Drug Candidate Derazantinib

* LICENSES LATE-STAGE ONCOLOGY DRUG CANDIDATE DERAZANTINIB FROM ARQULE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica: Partner Avir Pharma Launches Basilea's Ceftobiprole In Canada

* ITS PARTNER AVIR PHARMA INC HAS LAUNCHED BASILEA'S HOSPITAL ANTIBIOTIC ZEVTERA (CEFTOBIPROLE) IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica FY Operating Loss At CHF 14.1 million

* FY ‍54% INCREASE IN TOTAL REVENUE, AMOUNTING TO CHF 101.5 MILLION​

BRIEF-Basilea Pharmaceutica Reports Clinical Phase 3 Study Start With Antibiotic Ceftobiprole In Skin Infections

* REPORTS CLINICAL PHASE 3 STUDY START WITH ANTIBIOTIC CEFTOBIPROLE IN SKIN INFECTIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Appoints David Veitch As New CEO

* BASILEA'S CEO RONALD SCOTT WILL RETIRE. CHIEF COMMERCIAL OFFICER DAVID VEITCH NAMED AS SUCCESSOR. CHANGES IN THE BOARD OF DIRECTORS

BRIEF-Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​

* ‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​

BRIEF-Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA

* BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: